Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Scancell boss 'very excited' about collaboration deal with leading US lung cancer foundation

Scancell Holdings Plc (LON:SCLP) has confirmed it will kick off a phase II clinical trial of its potentially breakthrough cancer treatment in the second half.

CEO Richard Goodfellow also tells Proactive's Andrew Scott they've found a partner to help them with a phase I/II clinical study of SCIB2 for patients with lung cancer.

 
Meet Danakali, PNX Metals, Argent Minerals, Verdant Minerals and Oro Verde at our event, Sydney, 20 February 2017. Register here »
View full SCLP profile

Scancell Holdings Plc Timeline

Newswire
January 31 2017
Article
August 22 2016

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.